Subgroup analyses were performed by concurrent use of insulin and the presence of coronary heart disease; sensitivity analysis was performed by excluding patients with either valvular heart disease or cardiomyopathy and by excluding patients with heart failure (Table 2). This evidence concerns the gene INS and cardiomyopathy.